Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvisertib phase 1/2 study in myelofibrosis
2022-502597-16-00Phase 2Authorised
- Sponsor
- Sumitomo Pharma America
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label trial of nuvisertib and mivavotinib in primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
nuvisertibmivavotinib
03
Conditions
primary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on 2022-502597-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502597-16-00.